Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer

Inclusion Criteria: Participants must meet the following criteria on screening examination to be eligible to participate in the study. * Histologically or cytologically proven diagnosis of NSCLC or SCLC * NSCLC, patients with clinical stage IIB-IV patients (AJCC, 7th ed.) are eligible, and for SCLC, limited-stage patients are eligible, if documented to be a candidate for definitive radiation and concurrent chemotherapy in the radiation oncologist or medical oncologist clinic note. * Stage IV NSCLC patients are eligible only if they have a solitary brain metastasis * Patients with non-malignant pleural effusion are eligible. --- If a pleural effusion is present, the following criteria must be met to exclude malignant involvement: * When pleural fluid is visible on both the CT scan and on a chest x-ray, a pleuracentesis is required to confirm that the pleural fluid is cytologically negative. * Exudative pleural effusions are excluded, regardless of cytology; * Effusions that are minimal (ie, not visible on chest x-ray) that are too small to safely tap are eligible. * Gross tumor (primary tumor or involved lymph node) must be within 1 cm of esophagus on the most recent chest CT scan. * ECOG performance status 0-1 within 30 days prior to registration; * Age ≥18 * Women of childbearing potential must indicate that there is not a possibility of being pregnant at the time of enrollment or have a negative serum pregnancy test prior to the initiation of radiation t…